Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 3/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31036094 | 0.88 | MEN1 (0.47) | MTNR1AMTNR1BNAMPTRECQLMEN1 | |
| SCHEMBL19049445 | 0.84 | ACACB (0.49) | MTNR1AMTNR1BSMN1; SMN2ACACBNAMPT | |
| SCHEMBL8819 | 0.84 | NAMPT (0.52) | SMN1; SMN2NAMPTMEN1KMT2AP2RX7 | |
| SCHEMBL18997764 | 0.81 | POLB (0.45) | SMN1; SMN2NAMPTMEN1KMT2AP2RX7 | |
| SCHEMBL23222311 | 0.80 | KMT2A (0.44) | MTNR1ASMN1; SMN2NAMPTRECQLMEN1 | |
| SCHEMBL21776424 | 0.80 | NAMPT (0.38) | SMN1; SMN2ACACBNAMPTKMT2AP2RX7 | |
| SCHEMBL18381372 | 0.80 | SMN1; SMN2 (0.50) | SMN1; SMN2 | |
| SCHEMBL2093615 | 0.79 | SMN1; SMN2 (0.59) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL20805616 | 0.78 | NAMPT (0.37) | SMN1; SMN2NAMPTP2RX7 | |
| SCHEMBL19001317 | 0.77 | MTNR1A (0.44) | MTNR1AMTNR1BSMN1; SMN2ACACBRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402785-B1 | 3-(CARBOXYMETHYL)-8-AMINO-2-OXO-1,3-DIAZA-SPIRO-[4.5]-DECANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2020-02-26 | — | — | EP | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | MTNR1A 1704/4885MTNR1B 1599/4885SMN1; SMN2 4331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.